A high-profile, one-million-square-foot development along Highway 101 in South San Francisco has landed two up-and-coming biotech companies, Five Prime Therapeutics, Inc., and Global Blood Therapeutics, Inc., that, together, will take roughly a fifth of the project. Located at the epicenter of the life science and technology industries, The Cove at Oyster Point is an 875,000-square-foot, life science/tech campus featuring 20,000 square feet of on-site retail, a planned upscale hotel, green space, bay-front walking trails, an outdoor amphitheater, and other amenities. The campus consists of seven buildings ranging in size from just over 115,000 to 182,000 sq. ft., and can accommodate users from 30,000 sq. ft. to 847,000 sq. ft.
In December 2016, Five Prime Therapeutics Inc. (NASDAQ: FPRX) signed a lease for 115,466 square feet of the HCP Inc.-developed campus. The lease is for an initial five years, with a one-time option to extend it for an additional five years. Prices start at about $60 per square foot, and ramp up over a decade to more than $80.
Five Prime Therapeutics is a leader in the discovery and development of innovative protein therapeutics. It library of more than 5,700 human extracellular proteins substantially represents all of the body’s medically important targets for protein therapeutics. The clinical-stage biopharmaceutical company was founded in 2001, by Lewis T. “Rusty” Williams, M.D., Ph.D., who serves as its President and Chief Executive Officer. The company will fully occupy a proposed four-story, 115,466-square-foot office and laboratory facility at 111 Oyster Point Drive, and is expected to take occupancy upon the building’s completion in the fourth quarter of 2017.
On March 17, 2017, Global Blood Therapeutics, Inc. (NASDAQ:GBT) entered into a lease with HCP Oyster Point III LLC, for approximately 67,185 square feet of space in a building located at 171 Oyster Point Boulevard. The term of the lease will commence on the later of December 15, 2017, or the date that the premises are ready for occupancy, and will expire on the day prior to the tenth anniversary of the commencement. The Company has an option right to extend the lease term for a period of ten years.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span.
The 601W Company, a New York developer, has proposed building a 35-story hotel and residential tower atop an historic building at One Montgomery Street in San Francisco. The two- story building, once the headquarters of Crocker National Bank, and currently occupied by Wells Fargo & Co., which acquired Crocker in 1986, was originally built in 1908. 601W bought One Montgomery Street for $48 million in 2011.
The speculative plan for the 500-foot tower would add about 266,000 square feet of hotel and/or residential space to the city’s Financial District. Three possible plans have been filed, with various mixes of hotel and residential usage:
•234 hotel rooms and five market-rate residential units at the top five floors
•152 hotel rooms and 23 market-rate residential units
•52 market-rate residential units with no hotel rooms
None of the plans have affordable housing on-site. The first two plans wouldn’t be subject to the city’s new affordable housing requirements under Prop. C, which only apply to projects of 25 or more housing units. The 52-unit housing proposal could pay a fee equal to the value of 33 percent of the project’s units under Prop C instead of building affordable units. Some observers have speculated that the new affordability rules are pushing more projects to become hotels rather than housing.
While the addition of hotel space is likely to be welcomed by the city’s financial district, it remains to be seen if the city will actively consider the proposal to remake the character of an historic building. If approved, the One Montgomery St. project would be only the second new high-rise built in the area in over a decade as well as one of the biggest developments north of Market Street. The current two-story property would be preserved and renovated, and the existing entrance, at the southwest corner of the parcel, along Post Street, would be used for the new tower.